Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria

PloS One
Caroline SchmidbauerMichael Gschwantler

Abstract

Directly acting antivirals (DAA) against hepatitis C virus (HCV) infection have facilitated sustained virologic response (SVR) rates >90% in clinical studies. Yet, real life data regarding DAA treatment in people who inject drugs (PWIDs) are scarce. We evaluated the effectiveness of glecaprevir/pibrentasvir (G/P) in difficult-to-treat PWIDs with presumed high risk of non-adherence to DAA therapy using the concept of directly observed therapy involving their opioid substitution therapy (OST) facility. N = 145 patients (m/f: 91/54; median age: 41.1 (IQR 19.5) years; HCV-genotype (GT) 1/2/3/4: 82/1/56/5, GT3: 38.6%; cirrhosis: n = 6; 4.1%) treated with G/P were included. PWIDs at high risk for non-adherence to DAA therapy received HCV treatment together with their OST under the supervision of medical staff ("directly observed therapy", DOT). The effectiveness of G/P given as DOT in PWIDs with presumed high risk of non-adherence to DAA therapy was compared to patients with suspected "excellent compliance" in the "standard setting" (SS) of G/P prescription at a tertiary care center and self-managed G/P intake at home. Treatment duration was 8-16 weeks according to the G/P drug label. DOT-patients (n = 74/145; 51.0%) were younger tha...Continue Reading

References

Jan 14, 2016·Hepatology International·Mattias MandorferMarkus Peck-Radosavljevic
Jun 5, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Stephan MoserMichael Gschwantler
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN Polaris Observatory HCV Collaborators
Nov 9, 2017·Current HIV/AIDS Reports·David L Wyles
Nov 10, 2017·European Journal of Gastroenterology & Hepatology·Stephan MoserMichael Gschwantler
Nov 21, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Fred PoordadFederico J Mensa
Jan 25, 2018·The New England Journal of Medicine·Stefan ZeuzemFederico J Mensa
Jan 30, 2018·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Juan BerenguerJuan J González-García
Apr 14, 2018·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Jun 26, 2018·Journal of Hepatology·Luca Saverio BelliUNKNOWN all the contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)
Sep 25, 2018·The Lancet. Gastroenterology & Hepatology·Behzad HajarizadehJason Grebely
Nov 26, 2018·Journal of Hepatology·Roberta D'AmbrosioUNKNOWN NAVIGATORE-Lombardia Study Group
Mar 9, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiichi OgawaUNKNOWN Kyushu University Liver Disease Study (KULDS) Group
May 23, 2019·The New England Journal of Medicine·David L Thomas
Sep 13, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christiana GrafJohannes Vermehren

❮ Previous
Next ❯

Citations

Jan 16, 2021·Open Forum Infectious Diseases·Kristina M BrooksJennifer J Kiser
Jul 17, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Caroline SchmidbauerThomas Reiberger

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

RStudio
SPSS Statistics
Fibroscan

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.